You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永勝醫療(01612.HK)預期年度淨利同比減少不多於75%
格隆匯 01-27 16:38

永勝醫療(01612.HK)公吿,根據對集團截至2021年12月31日止年度未經審核綜合管理賬目以及公司目前可獲得資料的初步評估,預期年度公司擁有人應占溢利將較截至2020年12月31日止年度2.169億港元減少不多於75%。該減少主要歸因於以下因素:

於本年度,若干主要原材料和關鍵部件(主要為醫用級樹脂、醫用黏合劑、集成電路及印刷電路板)在全球出現短缺,導致原材料成本急劇上升,令集團難以迅速向客户轉嫁額外成本。

由於集團在中華人民共和國生產的產品當中,約80%乃以其他貨幣出口,故人民幣升值亦令本集團的毛利率受壓。此外,利潤率較高的醫療器械銷售減少令產品組合改變,以及總收入減少(如上所述)導致經營去槓桿化效應,繼而令毛利率下跌。

Fresca Medical,Inc.為一間美利堅合眾國("美國")睡眠解決方案及互聯健康公司,專注開發治療睡眠窒息症的系統。其為公司的一間聯營公司,於公吿日期,公司間接持有其約26.1%的股權,公司亦為Fresca的合約製造商。

根據目前可獲得資料,確認減值虧損與多項因素有關。該等因素包括Fresca於2021年的財務表現欠佳、需要對現有的SomneraTM系統(Fresca自2020年以來在美國市場推出的唯一醫療器械)進行實質性設計改進、睡眠窒息症治療器械市場競爭激烈,以及Fresca股東正就其業務前景及未來財務表現進行持續討論。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account